SCHEMBL1273585

SCHEMBL1273585

CCC(C(=O)O)N(C)C(=O)OC(C)(C)C

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP13 P45452 1/20 0.39
AAK1 Q2M2I8 2/20 0.36
MEN1 O00255 1/20 0.34
GAA P10253 1/20 0.34
KMT2A Q03164 1/20 0.34
HDAC6 Q9UBN7 2/20 0.33
CTSS P25774 2/20 0.33
CTSK P43235 2/20 0.33
HDAC1 Q13547 1/20 0.33
HDAC2 Q92769 1/20 0.33
REN P00797 1/20 0.32
NFKB1 P19838 1/20 0.31
NFKB2 Q00653 1/20 0.31
RELA Q04206 1/20 0.31
CA2 P00918 1/20 0.31
MAPK1 P28482 1/20 0.31
CA14 Q9ULX7 2/20 0.30
CA12 O43570 1/20 0.30
CA1 P00915 1/20 0.30
CA7 P43166 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1162878 1.00 MMP13 (0.39) MMP13AAK1MEN1GAAKMT2A
SCHEMBL953166 1.00 MMP13 (0.39) MMP13AAK1MEN1GAAKMT2A
SCHEMBL66573 0.86 HDAC1 (0.41) MMP13AAK1MEN1GAAKMT2A
SCHEMBL67491 0.86 HDAC1 (0.41) MMP13AAK1MEN1GAAKMT2A
SCHEMBL20826464 0.86 HDAC1 (0.41) MMP13AAK1MEN1GAAKMT2A
SCHEMBL626316 0.85 AAK1 (0.39) MMP13AAK1MEN1GAAKMT2A
SCHEMBL13335431 0.85 AAK1 (0.36) MMP13AAK1HDAC6CTSSCTSK
SCHEMBL7401175 0.85 MMP13 (0.39) MMP13AAK1MEN1GAAKMT2A
SCHEMBL626315 0.85 AAK1 (0.39) MMP13AAK1MEN1GAAKMT2A
SCHEMBL7401177 0.85 MMP13 (0.39) MMP13AAK1MEN1GAAKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 102 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025235719-A1 DIMERIC SMAC MIMETICS USEFUL IN HIV THERAPY VIIV HEALTHCARE COMPANY (US) 2025-11-13 WO disclosed
US-20250296915-A1 NOVEL AMINO ACID DERIVATIVES PEPTIDREAM INC (JP) 2025-09-25 US disclosed
US-20250281433-A1 NOVEL DERIVATIVE COMPOUND HAVING BIPHENYL GROUP INTRODUCED INTO AMINO-ALKANOIC ACID AND ANTI-INFLAMMATORY COMPOSITION COMPRISING SAME AMTIXBIO CO., LTD. (KR) 2025-09-11 US disclosed
US-12338230-B2 Aryl, heteroaryl, and heterocyclic compounds for treatment of immune and inflammatory disorders ACHILLION PHARMACEUTICALS, INC. (US) 2025-06-24 US disclosed
US-20250129099-A1 INHIBITOR OF APOPTOSIS (IAP) PROTEIN ANTAGONISTS Sanford Burnham Prebys Medical Discovery Institute 2025-04-24 US disclosed
US-20250074887-A1 PHARMACEUTICAL COMPOSITIONS OF 6-(2-(2H-TETRAZOL-5-YL)ETHYL)DECAHYDROISOQUINOLINE-3-CARBOXYLIC ACID AND DERIVATIVES THEREOF Sea Pharmaceuticals LLC. (US) 2025-03-06 US disclosed
US-12180139-B2 Method for preparing aminoalkanoic acid derivative containing biphenyl group AMTIXBIO CO., LTD. (KR) 2024-12-31 US disclosed
US-12172945-B2 Aminoalkanoic acid derivative containing biphenyl group and use of the same AMTIXBIO CO., LTD. (KR) 2024-12-24 US disclosed
US-12129220-B2 Pharmaceutical composition comprising aminoalkanoic acid derivative containing biphenyl group AMTIXBIO CO., LTD. (KR) 2024-10-29 US disclosed
CN-118845786-A Combination therapy 詹森药业有限公司 2024-10-29 CN disclosed
US-20090069294-A1 Organic Compounds NOVARTIS AG (CH) 2009-03-12 US disclosed
CN-101305019-A New cyclic peptide compounds ASTELLAS PHARMA INC (JP) 2008-11-12 CN disclosed
US-20080242658-A1 Inhibitors of Iap NOVARTIS AG (CH) 2008-10-02 US disclosed
US-7419975-B2 Organic compounds NOVARTIS AG (CH) 2008-09-02 US disclosed
EP-1902065-A2 CYCLIC AMIDE DERIVATIVES INHIBITORS OF THE INHIBITOR OF APOPTOSIS PROTEINS, THEIR PREPARATION, AND THEIR USE Novartis AG (CH) 2008-03-26 EP disclosed
CN-1964970-A Inhibitors of IAP NOVARTIS AG (CH) 2007-05-16 CN disclosed
EP-1735307-A1 INHIBITORS OF IAP Novartis AG (CH) 2006-12-27 EP disclosed
WO-2006133147-A2 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2006-12-14 WO disclosed
US-20050234042-A1 Organic compounds PALERMO MARK G 2005-10-20 US disclosed
WO-2005097791-A1 INHIBITORS OF IAP NOVARTIS AG (CH) 2005-10-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090069294-A1 Organic Compounds XIAP, BAX, MCL1 MMP13 4022/4885AAK1 4071/4885MEN1 2628/4885
US-20080242658-A1 Inhibitors of Iap XIAP, BIRC2, BIRC5 MMP13 2973/4885AAK1 1072/4885MEN1 2598/4885
US-12172945-B2 Aminoalkanoic acid derivative containing biphenyl group and use of the same GABBR1, AADAC, GABBR2 MMP13 2970/4885AAK1 1582/4885MEN1 4071/4885
US-20250129099-A1 INHIBITOR OF APOPTOSIS (IAP) PROTEIN ANTAGONISTS API5, XIAP, BIRC5 MMP13 2193/4885AAK1 664/4885MEN1 1418/4885
US-20250074887-A1 PHARMACEUTICAL COMPOSITIONS OF 6-(2-(2H-TETRAZOL-5-YL)ETHYL)DECAHYDROISOQUINOLINE-3-CARBOXYLIC ACID AND DERIVATIVES THEREOF GABRQ, GRIK5, CYP3A7 MMP13 2519/4885AAK1 4341/4885MEN1 1622/4885
US-20250296915-A1 NOVEL AMINO ACID DERIVATIVES DNPEP, BCAT1, ANPEP MMP13 3972/4885AAK1 1629/4885MEN1 2820/4885
US-12338230-B2 Aryl, heteroaryl, and heterocyclic compounds for treatment of immune and inflammatory disorders CFD, TFPI, CFH MMP13 2325/4885AAK1 2305/4885MEN1 2099/4885
US-20050234042-A1 Organic compounds AIFM1, BAX, API5 MMP13 3703/4885AAK1 2295/4885MEN1 3135/4885
US-12180139-B2 Method for preparing aminoalkanoic acid derivative containing biphenyl group AKR7A2, CYP51A1, APEH MMP13 2896/4885AAK1 1701/4885MEN1 3516/4885
US-20250281433-A1 NOVEL DERIVATIVE COMPOUND HAVING BIPHENYL GROUP INTRODUCED INTO AMINO-ALKANOIC ACID AND ANTI-INFLAMMATORY COMPOSITION COMPRISING SAME AADAT, AADAC, AHR MMP13 315/4885AAK1 1778/4885MEN1 4383/4885
US-12129220-B2 Pharmaceutical composition comprising aminoalkanoic acid derivative containing biphenyl group AHR, AADAC, GABBR1 MMP13 2426/4885AAK1 2040/4885MEN1 3534/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.